BioMarin Pharmaceutical, Inc. (NASDAQ:BMRN)

CAPS Rating: 4 out of 5

The Company develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.

Recs

1
Player Avatar nonothing2 (< 20) Submitted: 8/18/2008 5:01:17 PM : Underperform Start Price: $25.76 BMRN Score: +9.51

THis company is in a good market because Pharmeceuticals will always be needed, but a PE ration of 659 is simply unsustainable. A PE of above 40 is high, but this companies stock is over 600 times more expensive than its earnings per share. That's bad.

Member Avatar Reindom (77.90) Submitted: 9/4/2008 3:42:17 PM
Recs: 0

Not to mention the fact that if there is *any* bad news or negative press, speculators will abandon ship quickly. With p/e this high, the downside is much greater than the upside. In fact I don't see any upside with the price this high.

Featured Broker Partners


Advertisement